We report 4 patients in North America with disease caused by Emergomyces canadensis, a newly proposed species of pathogenic dimorphic fungus. Affected persons were immunocompromised; lived in Saskatchewan, Colorado, and New Mexico; and had systemic disease involving blood, skin, cervix, lung, and lymph node. Two cases were fatal.
M embers of the recently described fungal genus Emergomyces cause disseminated and often fatal disease in immunocompromised hosts (1, 2) . So named because of their recent global emergence (1), these dimorphic fungal pathogens have been reported from Africa, Asia, and Europe (3). Here we report from North America 4 cases of invasive fungal disease caused by a novel Emergomyces species, designated Es. canadensis.
The Study
In 2003, a 39-year-old man with a history of diabetes and a cadaveric renal transplantation 3 years prior visited a hospital in Saskatoon, Saskatchewan, Canada, reporting fever and throat pain. His medications included mycophenolate and prednisone (25 mg/d). The patient had no history of travel. He kept pet birds, none of which were ill, and had no other animal exposures.
On examination, the patient was cushingoid, normotensive, and afebrile. Results of oropharyngeal, chest, and abdominal examinations were unremarkable. Chest radiograph and computed tomography demonstrated diffuse micronodules, left upper lobe consolidation, and mediastinal lymphadenopathy. The patient was assessed by esophagoscopy, which indicated white, dry patches suspicious for esophageal candidiasis; consequently, we started him on oral fluconazole (200 mg/d). On day 5 postadmission, he had myalgias, arthralgias, and a fever of 38.9°C, prompting collection of mycobacterial and fungal blood cultures. Two days later, a bronchoscopy demonstrated white patches in the trachea and bronchi. On day 17 of admission, both the blood and bronchoalveolar lavage cultures grew a fungus. Repeated blood cultures subsequently grew the same fungus. We treated the patient with lipid complex amphotericin B for 3 weeks, with clinical improvement, and he was discharged after 7 weeks in the hospital.
Several days later, the patient returned, reporting weakness, postural dizziness, anorexia, and vomiting. Repeated chest radiograph and computed tomography showed patchy consolidation with increased right mediastinal lymphadenopathy. A mediastinoscopy with lymph node biopsy excluded lymphoma. No material was sent for culture, but histopathologic examination with fungal stains demonstrated small, round or oval yeasts ( Figure  1 ). The patient remained afebrile, and he was managed expectantly without additional antifungal therapy. His symptoms resolved, and he was discharged. Serial chest radiographs demonstrated resolution of the mediastinal lymphadenopathy, and no clinical relapse occurred in 3 years of follow-up.
The clinical isolate was referred to the University of Alberta Microfungus Collection and Herbarium (UAMH) for characterization and identification. The fungus grew as a mold phase at 30°C and as a yeast at 35°C ( DNA genetic analysis was performed by sequencing the internal transcribed spacer region and D1/D2 domain of the large subunit rDNA as previously described (4) . We compiled and summarized epidemiologic and clinical data from submitting laboratories and clinicians for the 4 clinical Es. canadensis isolates (Table) . Two isolates were referred from Saskatchewan, 1 from Colorado, and 1 from New Mexico. All 3 patients for whom medical histories could be ascertained were immunocompromised, 2 with advanced HIV infection and the third with a kidney transplantation. Histopathology results were available for 2 patients: in case 2, small yeasts were observed in tissue from mediastinal lymph node, and in case 3, in tissue from an endocervical mass. Es. canadensis was cultured from biopsied cutaneous lesions in 2 patients (in cases 1 and 4). For 2 remaining patients, Es. canadensis was cultured from blood, and additionally in 1 patient, from bronchoalveolar fluid. Two patients survived, and 2 died.
We performed limited antifungal susceptibility testing for 2 isolates (6). The MIC of UAMH 10370 was 0.125 µg/mL for amphotericin B. The MIC of UTHSCSA DI17-85 was 64 µg/mL for fluconazole and 0.125 µg/mL for itraconazole.
Conclusions
Es. canadensis is one of several newly recognized species within Emergomyces (2), and causes an endemic mycosis in North America, where it should be considered in immunocompromised hosts with systemic disease. Es. africanus causes the most common endemic mycosis in South Africa, primarily affecting HIV-infected persons (7); pulmonary and cutaneous disease are common, and the case-fatality rate is 50% (8) . Invasive disease caused by Es. pasteurianus (previously Emmonsia pasteuriana [2, 9] ) has been reported from Italy, Spain, France, India, China, and South Africa (3). Es. orientalis was reported just once, from a man in China (10) . Infection caused by another novel species, Es. europaeus, is known also from a single case from Germany (11) .
Limited antifungal susceptibility testing of 2 Es. canadensis isolates found MICs elevated for fluconazole and low for itraconazole and amphotericin B. Dukik et al. (12) recently reported antifungal susceptibility results for 2 Es. canadensis isolates including UAMH 7172 (reported as CBS 139872) and UAMH 10370 (reported as CBS 139873). The authors similarly found that MICs were elevated for fluconazole and low for newer triazoles and amphotericin B (12) . These findings are consistent with the antifungal susceptibility patterns reported for 50 Es. africanus isolates (7). The anecdotal observation in our study that a patient (in case 2) remained fungemic with Es. canadensis 2 weeks after initiating fluconazole but had rapid clinical improvement with amphotericin B is consistent with these in vitro results. Pending the availability of further data, treatment of disease caused by Emergomyces spp. infection should follow clinical practice guidelines for the management of other dimorphic fungal infections in immunocompromised hosts (13) . Specifically, treatment should include amphotericin B (lipid formulation 3-5 mg/kg or deoxycholate 0.7-1.0 mg/kg) for 1-2 weeks, followed by itraconazole (or other newer triazole) for at least 12 months, depending on immune reconstitution (13) .
This report raises many questions about the pathogenesis, distribution, and habitat of Es. canadensis. As is the case for other dimorphic fungi, inhalational infection by Emergomyces spp. is presumed to occur, followed by extrapulmonary dissemination and disease in susceptible hosts (3) . Although limited by small numbers and the lack of travel histories, these cases suggest that the geographic range of Es. canadensis likely involves central and western regions of North America. An ecologic niche has only been investigated for Es. africanus, which has been detected from various soil habitats and in air samples from Cape Town, South Africa (14, 15 
